AP24534-12-202: Phase 2 Trial of Ponatinib in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Following Failure of Prior Therapy with at Least 1 Tyrosine Kinase Inhibitor
The purpose of this study is to find out if ponatinib (the study drug), is safe and has beneficial effects in people with metastatic and/or unresectable GIST who have failed at least one TKI therapy.
Unresectable or metastatic GIST
1. Adults aged 18 years or above.
2. Histologically confirmed diagnosis of metastatic and/or unresectable GIST
3. Must have failed at least 1 prior treatment with a TKI
4. Other criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression or unacceptable side effect.
Tracy Walker, RN (503) 346-1183 or email@example.com